DAYLI Partners — 2025 Investments

1 investments dated 2025 · listed companies and verified rows first · show all

D&D Pharmatechddpharmatech.com inJun 2025

DD Pharmatech develops therapeutics for metabolic disorders, with a focus on oral and long-acting GLP-1 receptor agonist formulations.

Biotech

Seulki Lee(Executive Officer, Director)inSunghoon Hong(Executive Officer, Director)Sungmook Lim(Executive Officer, Director)

BoardDaehyun Shin(Director)Seungwon Lim(Director)Seol-Heui Han(Director)

Co-investorsKiwoom Investment LB Investment Magna Investment Octave Ventures Llc

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.